Corvidia Therapeutics Inc., a leading clinical stage biotechnology company, today announced the close of a $60 million USD Series B funding round. The financing will accelerate growth of Corvidia’s ongoing clinical programs, expand scientific and market access capabilities and explore new treatment areas.
Patients dealing with hypotension, or dangerously low blood pressure, can now be treated with a drug initially developed by George Washington University researcher Lakhmir Chawla from the School of Medicine and Health Sciences and the GW Medical Faculty Associates.
Towson University celebrated the start of construction on the new science complex with a groundbreaking ceremony on the top floor of the Glen Garage April 17.
Construction for the new science complex began in fall 2017, but the ceremony marked the University officially breaking ground on the project.
The annual BioHealth forum brought together about 1,100 biotech industry stakeholders from across Maryland, Washington, D.C., and Virginia.
George Mason University President Angel Cabrera said more restrictive immigration policies could threaten the future of regional and national biotechnology industries.
“It is critical for universities to act both as producers of [science, technology, engineering and math] talent and as magnets for top STEM faculty and researchers from around the world. That is our biggest role in the ecosystem,” Cabrera said. “When we mess with immigration policy, our whole system of science and innovation is at stake.
Prince William County today congratulated three science start-ups – ISOThrive, LLC, Virongy, LLC and Ceres Nanosciences, Inc., – on recent business successes leading from the Prince William Science Accelerator.
The Emmes Corporation today announced the creation of an internship program in which the company will offer one fellow from Egypt’s Children Cancer Hospital an internship to gain training and experience in clinical research. Under the new program, one fellow will be selected each year to travel to Emmes’ headquarters in Rockville, Maryland, to work with its clinical research experts. The duration of each internship will be determined on a case-by-case basis.
Q Therapeutics, Inc., a developer of clinical-stage cell therapies for central nervous system (CNS) diseases, and REPROCELL Inc., Japan’s first induced pluripotent stem cell (iPSC) company, announced the formation of MAGiQ Therapeutics, Inc., a Japanese joint venture company. MAGiQ will develop iPSC-derived, glial-restricted progenitor cells (GRPs), in collaboration with Q Therapeutics and REPROCELL, to treat demyelinating and degenerative diseases of the CNS.
New York investment firm Deerfield Management is looking to bring more drugs, medical devices and health care products to market by partnering with academic institutions like Johns Hopkins University.
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. regulatory approval of PartoSureTM , which is a novel test for assessing the risk of spontaneous preterm birth in patients with symptoms of preterm labor. The pre-market approval of PartoSure by the U.S. Food and Drug Administration (FDA) follows successful uptake of the rapid, accurate test in more than 35 countries across Europe, the Middle East, Asia and Latin America. U.S. commercialization of the PartoSure test is expected to begin in 2018.
